Pyrrolo [2,3-d] pyrimidine and their use as purinergic...

Details Pyrrolo [2,3-d] pyrimidine and their use as purinergic... Pyrrolo [2,3-d] pyrimidine and their use as purinergic...

2006-01-27

2009-10-06

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S280000

Reexamination Certificate

active

07598256

ABSTRACT:
Use of a compound of the formula (I) wherein R1is selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NR7R8, NR6COR7, NR6CO2R9and NR6SO2R9; R2is selected from aryl attached via an unsaturated carbon; R3and R4are independently selected from H, alkyl, halogen, alkoxy, alkylthio, CN and NR7R8; R5is selected from H, acyclic alkyl, COR6, CONR7R8, CONR6NR7R8, CO2R9and SO2R9; R6, R7and R8are independently selected from H, alkyl and aryl or where R7and R8are in an NR7R8group R7and R8may be linked to form a hererocyclic group, or where R6, R7and Rsare in a (CONR6NR7Rs) group, R6and R7may be linked to form a hererocyclic group; and R9is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subect; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.

REFERENCES:
patent: 0 496 617 (1992-07-01), None
patent: 07010876 (1995-01-01), None
patent: WO 93/20078 (1993-10-01), None
patent: WO 94/13676 (1994-06-01), None
patent: WO 94/17803 (1994-08-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/21617 (1999-05-01), None
patent: WO 99/62518 (1999-12-01), None
patent: WO 00/61586 (2000-10-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Kulisevsky, Jaime; Barbanoj, Manel; Gironell, Alexandre; Antonijoan, Rosa; Casas, Miquel; Pascual-Sedano, Berta, Clinical Neuropharmacology. 25(1):25-31, Jan./Feb. 2002, abstract only.
Morelli, Micaela, Experimental Neurology, 184, 20-23, 2003.
Tuite, Paul et al, Expert. Opin. Investig. Drugs, 12, 1335-1352, 2003.
Bibbiani, F. et al, Experimental Neurology, 184, 285-294, 2003.
Spiros Konitsiotis, Expert. Opin. Investig. Drugs, 14, 377-392 2005.
Anonymous, Drug and Therapeutic Bulletin, 35, pp. 36-40, 1999.
LeWitt, Peter A., Pharmacotherapy, 20, pp. 26S-32S, 2000.
Joergensen, Anker; Girgis, Nabih S.; Erik B., Liebigs Annalen der Chemie (1), 142-8 (English) 1985.
Cocuzza et al., “Use of the suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists,”Bioorganic&Medicinal Chemistry Letters(Apr. 5, 1999), vol. 9, No. 7, pp. 1063-1066, XP004162586, ISSN: 0960-894X.
Suzuki, Hitomi et al: “Sodium telluride in N-methyl-2-pyrrolidone. Reduction of aromatic carbronyl compounds to alcohols and formation of pyrrolo[2,3-d]pyrimidines (7-deaza-9H-purines) from aromatic nitriles,” XP002197327, RN:144587-22-4, 144587-23-5, 144587-24-6, abstract & J. Org. Chem. (1993), 58(1), 241-4.
Bouillon, Jean Philippe et al.: “Trifluoromethylated pyrimidines starting from.beta.-trifluoroacetyl-lactams,-lactone and -cyclanone,” XP002197328, RN: 156870-48-3, abstract, & Heterocycles (1994), 37(2), 915-32.
Le Witt,Pharmacotherapy, 20, pp. 26S-32S, 2000.
Joergensen et al.,Liebigs Annalen der Chamie, (1), 142-8 (English), 1985.
Tuite et al.,Expert. Opin. Investig. Drugs, 12, 1335-1352, 2003.
Bibbiani et al.,Experimental Neurology, 184, 285-294, 2003.
Konitsiotis,Expert Opin. Investig. Drugs, 14, 377-392, 2005.
Anonymous,Drug and Therapeutic Bulletin, 37, 36-40, 1999.
Wolff, “Burger's Medicinal Chemistry, 5 ed, Part 1,” John Wiley & Sons, 1995, pp. 975-977,
Banker et al., “Modern Pharmaceutics, 3ed,” Marcel Dekker, New York , 1996, pp. 451 and 596.
Kulisevsky et al.,Clinical Neurophamacology, 25(1):25-31, Jan./Feb. 2002, abstract only.
Morelli et al.,Experimental Neurology, 184, 20-23, 2003.

Affiliated with

Also associated with

Rating

Pyrrolo [2,3-d] pyrimidine and their use as purinergic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo [2,3-d] pyrimidine and their use as purinergic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo [2,3-d] pyrimidine and their use as purinergic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4140967